Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

NCT03199274 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: Yttrium-90 Microsphere Radioembolization
DRUG: Perflutren Protein-Type A Microspheres
PROCEDURE: Dynamic Contrast-Enhanced Ultrasound Imaging

Sponsor

Thomas Jefferson University

Collaborators

[object Object]
[object Object]